Innovative drugs arrive with a dropper

Access to innovative medicines and therapies has become one of the main examples of health inequalities in European countries. This disparity is evident in the WAIT survey, published by the consulting firm Iqvia, which collects data on 152 of these drugs authorized by agencies amid 2016 and 2019 lifebloombeauty.

Spain is below the chief members of the European Union in terms of access. In addition, the report emphasizes that the area where our country has the lowest records is the mismatch between authorization, obtaining public funding and making it available to patients futuretechexpert.

According to data updated on 31 December 2020, only 82 medicines were available in Spain out of the 152 authorized between 2016 and 2019. This corresponds to just over half, 54%, of the new compounds approved in Europe. . In addition, it takes an average of 453 days to be obtainable. For this motive, access to therapeutic compounds presents major challenges that require solutions to mitigate the impact of delayed innovation naturalbeautytrends.

According to Humberto Arnés, CEO of Farmmaindustria, “There is no point in developing the best medicine if it does not reach the persistent who needs it. After the long process of research and development of new drugs, which is an improvement in the conduct of diseases, it is everyone's responsibility to make them available to patients as soon as possible, "explains Arnés techsmartinfo .

The Federation of Spanish Scientific Medical Associations (Facme) addresses the delay in decision-making, which causes delays. Cristina Avendaño, a member of the entity and head of the Covid-19 vaccination group, emphasizes that the key challenge would be to reform the current system in the face of the coexistence of therapeutic and financial evaluations smarttechpros  “which are subject to differentiated and public evaluations. evaluations ... gossips. "

 

The automatic and the consequence of the delay are hurt by specific diseases, such as cancer. "We need to make sure that all patients have access to innovation in times of competition. In oncology, adapted treatment is a key element that improves research and it is essential to make further progress, ”explains Enriqueta Felip, Vice President of the Spanish Society. Medical Oncology (SEOM). Indeed, the delay in the availability of actions means, according to Philip, "that some patients do not receive them, with consequences that affect survival and / or quality of life."

"In recent years, mortality from metastatic disease has declined globally from 1% to 3% due to the incorporation of new systemic treatments. The longer the delay, the fewer mortality we will have, ”said Rafael López, president of the ECO Foundation. And this situation generates in patients "a loss of opportunities and a completely unnecessary burden of anxiety," adds López.

 

To solve the problem, a possible solution is to mimic the speed with which vaccination against the covid-19 pandemic was carried out. Pilar Martínez, president of the General Alliance of Patients (AGP), has an impact on this point: “Vaccines have shown that approval processes can be shortened. Without taking the pandemic as an example, it is clear that there is room for improvement in all approval procedures. "

Sources from the Office of Health assure MUY that a procedure is being developed: “This involves establishing an accelerated evaluation mechanism to reduce processing times in the funding procedure. And the price. New from a medical point of view; in particular, from the submission of the tender dossier by the laboratory holding the medicinal product to the inclusion of the dossier on the agenda of the Interministerial Commission for the Price of Medicinal Products (CIPM).

This is in addition to the measures already booked by Well-being, which has been working for some time to speed up the arrival of medicines in hospitals. To this end, the REvalMed platform has been created, which aims to evaluate compounds or establish specific mechanisms for faster evaluation.

The political sphere also offers various solutions, such as "acting during the trial period and in terms of human and economic resources", according to Guillermo Díaz, spokesman for Citizen Health in Congress. For his part, Podemos advocates a "public pharmaceutical industry" as a solution to shortages. "The military pharmacy could be a decent starting point," added Rosa Medel, Violet's representative in the lower house.

Elvira Velasco, a spokeswoman for PP Health in Congress, said it was important for administrative procedures to "meet legal deadlines as much as possible." In this context, he proposes a visa review